Journal
MOLECULAR ONCOLOGY
Volume 11, Issue 1, Pages 62-78Publisher
WILEY
DOI: 10.1016/j.molonc.2016.09.009
Keywords
breast cancer; cancer; dormancy; latency; metastasis
Categories
Funding
- La Caixa PhD fellowship
- Institucio Catalana de Recerca i Estudis Avancats
- BBVA Foundation
- Generalitat de Catalunya [SGR 535]
- Spanish Ministerio de Economia y Competitividad (MINECO)
- FEDER [SAF2013-46196-R, SAF2016-76008-R]
Ask authors/readers for more resources
Metastasis is the primary cause of death in cancer patients and current treatments fail to provide durable responses. Efforts to treat metastatic disease are hindered by the fact that metastatic cells often remain dormant for prolonged intervals of years, or even decades. Tumor dormancy reflects the capability of disseminated tumor cells (DTCs), or micrometastases, to evade treatment and remain at low numbers after primary tumor resection. Unfortunately, dormant cells will eventually produce overt metastasis. Innovations are needed to understand metastatic dormancy and improve cancer detection and treatment. Currently, few models exist that faithfully recapitulate metastatic dormancy and metastasis to clinically relevant tissues, such as the bone. Herein, we discuss recent advances describing genetic cell-autonomous and systemic or local changes in the microenvironment that have been shown to endow DTCs with properties to survive and eventually colonize distant organs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available